Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism

Launched by ASSIUT UNIVERSITY · Aug 7, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two different treatments for patients with acute intermediate-high pulmonary embolism, a serious condition where blood clots block the blood vessels in the lungs. The study will look at how well these treatments work in the hospital and how patients feel one month after treatment. One group of participants will receive systemic thrombolysis, which involves using medications like streptokinase or TPA to dissolve the clots. The other group will receive catheter-directed management, where a special device called the Penumbra System is used to help remove the clots directly.

To be eligible for the trial, participants must be diagnosed with acute intermediate-high pulmonary embolism and be between the ages of 65 and 74. However, those who are under 18, have a lower risk of pulmonary embolism, or have certain other conditions may not qualify. If you choose to participate, you can expect to receive one of the two treatments and be monitored closely for your health outcomes during your hospital stay and for one month afterward. It's important to know that participation is voluntary, and you can decide not to take part if you prefer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with acute intermediate-high pulmonary embolism
• Exclusion Criteria:
• • Patients less than 18 years of age.
• • Low risk, intermediate low risk, acute pulmonary embolism
• • patients with RV masses will be excluded.
• • Patient refusal of treatment strategy.